Compare IMUX & MCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IMUX | MCN |
|---|---|---|
| Founded | 2016 | 2004 |
| Country | United States | Canada |
| Employees | 66 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.6M | 123.7M |
| IPO Year | 2013 | N/A |
| Metric | IMUX | MCN |
|---|---|---|
| Price | $1.01 | $5.98 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $4.50 | N/A |
| AVG Volume (30 Days) | ★ 2.1M | 55.5K |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.96% |
| EPS Growth | ★ 38.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.51 | $5.21 |
| 52 Week High | $1.51 | $6.39 |
| Indicator | IMUX | MCN |
|---|---|---|
| Relative Strength Index (RSI) | 42.29 | 56.42 |
| Support Level | $0.62 | $5.85 |
| Resistance Level | $1.17 | $6.02 |
| Average True Range (ATR) | 0.11 | 0.08 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 14.06 | 90.91 |
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
XAI Madison Equity Premium Income Fund is an investment management company. The Fund invests in an actively managed equity portfolio comprised of individual stocks and covered call options. The Fund's primary investment objective is to provide high level of current income and gains, with a secondary objective of capital appreciation.